Will gene therapy trump factor treatment in hemophilia?
Centre for Haemostasis & Thrombosis, Guy's & St Thomas' NHS Foundation Trust, 1st Floor North Wing, St Thomas' Hospital, Westminster Bridge Road, London, SE1 7EH, UK. .Expert Review of Hematology (Impact Factor: 2.07). 02/2013; 6(1):43-8. DOI: 10.1586/ehm.12.70
Hemophilia treatment is entering a new phase, with the exciting possibility of gene therapy promising a cure. Novel gene transfer strategies are being considered for patients with inhibitors.Improvement of factor-replacement therapy is being aggressively pursued with long-acting factor concentrates, many of which are in clinical trials. Whether gene therapy will be safe and cost effective to eventually supersede factor-replacement therapy is yet to be determined. It is hoped that with the profusion of clinical trial programs in hemophilia care, it will eventually provide affordable treatment to many patients who currently cannot access adequate treatment in the developing countries.
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.